iCAD Inc (ICAD) just unveiled an announcement.
iCAD, Inc. has enriched its Board of Directors with the appointment of Dr. Hedvig Hricak, a distinguished figure in the medical field with extensive experience in molecular pharmacology and radiology. Dr. Hricak, who brings a wealth of knowledge from her time at prestigious institutions and has received numerous accolades, including the National Academy of Medicine’s David Rall Medal, was granted an option to purchase 40,000 shares of iCAD’s common stock. This move signals iCAD’s commitment to leveraging Dr. Hricak’s expertise to enhance their strategic direction and governance within the medical technology landscape.
For detailed information about ICAD stock, go to TipRanks’ Stock Analysis page.
